Natera Inc (NTRA) reported quarterly earnings results on Tuesday, May-10-2016. The company said it had a profit of $-0.17 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.29. Analysts had a consensus of $-0.46. The company posted revenue of $61.90 million in the period, compared to analysts expectations of $49.74 million. The company’s revenue was up 30.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.89 EPS.
Many Wall Street Analysts have commented on Natera Inc. The Benchmark Company Initiated Natera Inc on Apr 19, 2016 to “Buy”, Price Target of the shares are set at $14.
Natera Inc opened for trading at $9.27 and hit $9.6 on the upside on Friday, eventually ending the session at $9.57, with a gain of 2.13% or 0.2 points. The heightened volatility saw the trading volume jump to 86,980 shares. Company has a market cap of $487 M.
In a different news, on Feb 3, 2016, Jonathan Sheena (Chief Technology Officer) sold 10,000 shares at $8.03 per share price. According to the SEC, on Jan 5, 2016, Matthew Rabinowitz (CEO, President) sold 54,683 shares at $10.22 per share price. On Jul 9, 2015, James Healy (director) purchased 350,000 shares at $18.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Natera Inc. is a diagnostics company. The Company has molecular and bioinformatics technology that it deploys to change genetic diseases across the world. Its molecular assays measure various regions across the genome from samples as small as a single cell. Its statistical algorithms combine these measurements with the available data to detect a range of serious conditions. It is engaged in developing products for various oncology applications. In addition to its direct sales force in the United States the Company has a global network of over 70 laboratory and distribution partners. It has introduced a cloud-based distribution model. It also has launched seven molecular diagnostic tests. The Company launched Panorama which is its non-invasive prenatal test (NIPT). Its products include Pre-implantation Genetic Screening Pre-implantation Genetic Diagnosis Products of Conception Non-Invasive Paternity Testing High Throughput Carrier Screening and Non-Invasive Prenatal Testing.